PLSE
MIAMI - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nano-PFA or nsPFA) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Pulse Biosciences' Management is scheduled to present on Wednesday, January 15, 2025, at 3:45 pm PT. A live and recorded webcast of the presentation will be available on the 'Events Calendar and Presentations' page of the company's investor website at http://investors.pulsebiosciences.com/.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine Company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
Contact:
Darrin Uecker
Email: CCOIR@pulsebiosciences.com
Philip Trip Taylor
Tel: 415.937.5406
Email: philip@gilmartinir.com
(C) 2025 Electronic News Publishing, source ENP Newswire